All In Biotech

Drug Trial Radar · NCT00223080

HIV Vaccine Trial in Thai Adults

A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults

Last checked: Nov 20, 2026Latest source record: Apr 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 16,402 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

16,402

Actual

Start

Oct 2003

Primary completion

Jul 2006

Study completion Jun 2009

Sponsor

Sponsor type
Federal agency
Collaborators
United States Army Medical Materiel Development Activity; Armed Forces Research Institute of Medical Sciences, Thailand; Walter Reed Army Institute of Research (WRAIR); MCM Vaccines B.V.; VaxGen; The Emmes Company, LLC; Ministry of Health, Thailand; Mahidol University; Royal Thai Army Medical Department; Tripler Army Medical Center; Henry M. Jackson Foundation for the Advancement of Military Medicine
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in healthy Thai volunteers.

Conditions

  • HIV Infection

Interventions

  • ALVAC-HIV vCP1521 + AIDSVAXBiological

    Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL

  • ALVAC Placebo + AIDSVAX PlaceboOther

    ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat PopulationTime frame: 42 Months
  2. Vaccine Efficacy as Determined by Acquisition of Infection in the Per-protocol PopulationTime frame: 42 Months
  3. Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the MITT PopulationTime frame: 42 months
  4. Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the Per Protocol PopulationTime frame: 42 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Ban Lamung District Hospital

    Ban Lamung District, Changwat Chon Buri, Thailand

  • Phan Tong District Hospital

    Phan Tong District, Changwat Chon Buri, Thailand

  • Sattahip District Hospital

    Sattahip District, Changwat Chon Buri, Thailand

  • Ao Udom Hospital

    Sri Racha District, Changwat Chon Buri, Thailand

  • Ban Chang District Hospital

    Ban Chang District, Changwat Rayong, Thailand

  • Ban Khai District Hospital

    Ban Khai District, Changwat Rayong, Thailand

  • Klaeng District Hospital

    Klaeng District, Changwat Rayong, Thailand

  • Provincial Health Office

    Muang District, Changwat Rayong, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.